PURPOSE: Lymphoma is the commonest pediatric cancer in sub-Saharan Africa (SSA). Frequent treatment abandonment contributes to suboptimal outcomes. We examined risk factors and reasons for treatment abandonment for this population in Malawi. METHODS: We conducted a mixed methods study among children < 18 years old with newly diagnosed lymphoma, prospectively enrolled during 2013-2016. All children received standardized diagnosis and treatment, and were followed for up to 2 years. Treatment abandonment was defined as failure to attend prescribed chemotherapy within 4 weeks, or post-treatment visit within 3 months. Child, guardian, and household characteristics associated with treatment abandonment were assessed. Semi-structured interviews were conducted with primary caregivers of children experiencing treatment abandonment. RESULTS: Of 121 children with newly diagnosed lymphoma, 72 (60%) had complete information regarding child, guardian, and household characteristics. Of these, 56 (78%) had Burkitt's and 16 (22%) Hodgkin's lymphoma. Forty-nine (68%) were male, median age was 10.6 years (interquartile range [IQR] 7.9-13.0), and 26 (36%) experienced treatment abandonment. Lack of guardian education and travel time ≥ 4 h to clinic were independently associated with treatment abandonment, with adjusted hazard ratio (aHR) 3.8 [95% confidence interval (CI) 1.5-8.9, p = 0.005] and aHR 2.9 (95% CI 1.2-6.9, p = 0.019), respectively. Commonest reasons for treatment abandonment endorsed by 15 guardians were community influence, suboptimal clinic environment, logistical challenges, transport costs, treatment toxicities, loss of hope, alternative healers, and beliefs about cure. CONCLUSIONS: These findings highlight families at risk for treatment abandonment, underlying reasons, and opportunities to improve retention in care for pediatric cancer patients in SSA.
PURPOSE:Lymphoma is the commonest pediatric cancer in sub-Saharan Africa (SSA). Frequent treatment abandonment contributes to suboptimal outcomes. We examined risk factors and reasons for treatment abandonment for this population in Malawi. METHODS: We conducted a mixed methods study among children < 18 years old with newly diagnosed lymphoma, prospectively enrolled during 2013-2016. All children received standardized diagnosis and treatment, and were followed for up to 2 years. Treatment abandonment was defined as failure to attend prescribed chemotherapy within 4 weeks, or post-treatment visit within 3 months. Child, guardian, and household characteristics associated with treatment abandonment were assessed. Semi-structured interviews were conducted with primary caregivers of children experiencing treatment abandonment. RESULTS: Of 121 children with newly diagnosed lymphoma, 72 (60%) had complete information regarding child, guardian, and household characteristics. Of these, 56 (78%) had Burkitt's and 16 (22%) Hodgkin's lymphoma. Forty-nine (68%) were male, median age was 10.6 years (interquartile range [IQR] 7.9-13.0), and 26 (36%) experienced treatment abandonment. Lack of guardian education and travel time ≥ 4 h to clinic were independently associated with treatment abandonment, with adjusted hazard ratio (aHR) 3.8 [95% confidence interval (CI) 1.5-8.9, p = 0.005] and aHR 2.9 (95% CI 1.2-6.9, p = 0.019), respectively. Commonest reasons for treatment abandonment endorsed by 15 guardians were community influence, suboptimal clinic environment, logistical challenges, transport costs, treatment toxicities, loss of hope, alternative healers, and beliefs about cure. CONCLUSIONS: These findings highlight families at risk for treatment abandonment, underlying reasons, and opportunities to improve retention in care for pediatric cancerpatients in SSA.
Authors: Meaghann S Weaver; Ramandeep S Arora; Scott C Howard; Carmen E Salaverria; Yen-Lin Liu; Raul C Ribeiro; Catherine G Lam Journal: Pediatr Blood Cancer Date: 2015-01-13 Impact factor: 3.167
Authors: Christopher C Stanley; Kate D Westmoreland; Salama Itimu; Ande Salima; Toon van der Gronde; Peter Wasswa; Idah Mtete; Mercy Butia; Nader K El-Mallawany; Satish Gopal Journal: Pediatr Blood Cancer Date: 2016-11-28 Impact factor: 3.167
Authors: Trijn Israëls; Chawanangwa Chirambo; Huib Caron; Jan de Kraker; Elizabeth Molyneux; Ria Reis Journal: Pediatr Blood Cancer Date: 2008-11 Impact factor: 3.167
Authors: Jeremy S Slone; Catherine Chunda-Liyoka; Marta Perez; Nora Mutalima; Robert Newton; Chifumbe Chintu; Chipepo Kankasa; James Chipeta; Douglas C Heimburger; Sten H Vermund; Debra L Friedman Journal: PLoS One Date: 2014-02-21 Impact factor: 3.240
Authors: Grace K Ellis; Agness Manda; Hillary Topazian; Christopher C Stanley; Ryan Seguin; Caroline E Minnick; Blessings Tewete; Asekanadziwa Mtangwanika; Mena Chawinga; Sara Chiyoyola; Maria Chikasema; Ande Salima; Stephen Kimani; Edwards Kasonkanji; Victor Mithi; Bongani Kaimila; Matthew S Painschab; Satish Gopal; Katherine D Westmoreland Journal: Int Health Date: 2021-04-27 Impact factor: 2.473
Authors: Maya Jane Bates; Adamson Muula; Stephen B Gordon; Marc Y R Henrion; Ewan Tomeny; Peter MacPherson; Bertel Squire; Louis Niessen Journal: Wellcome Open Res Date: 2020-03-02
Authors: Maya Jane Bates; Miriam R P Gordon; Stephen B Gordon; Ewan M Tomeny; Adamson S Muula; Helena Davies; Claire Morris; Gerald Manthalu; Eve Namisango; Leo Masamba; Marc Y R Henrion; Peter MacPherson; S Bertel Squire; Louis W Niessen Journal: Lancet Glob Health Date: 2021-10-29 Impact factor: 38.927
Authors: James C Dickerson; Paulette Ibeka; Itoro Inoyo; Olufolarin O Oke; Sunday A Adewuyi; Donna Barry; Abubakar Bello; Olufunke Fasawe; Philip Garrity; Muhammad Habeebu; Franklin W Huang; Vivienne Mulema; Kenneth C Nwankwo; Danna Remen; Owens Wiwa; Ami S Bhatt; Mohana Roy Journal: JCO Glob Oncol Date: 2021-09
Authors: Alyssa E Tilly; Grace K Ellis; Jane S Chen; Agness Manda; Ande Salima; Asekanadziwa Mtangwanika; Blessings Tewete; Bongani Kaimila; Edwards Kasonkanji; Ella Kayira; Maria Chikasema; Ruth Nyirenda; Samuel Bingo; Sara Chiyoyola; Ryan Seguin; Satish Gopal; Takondwa Zuze; Tamiwe Tomoka; Katherine D Westmoreland Journal: JCO Glob Oncol Date: 2022-02